Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Preferred Stock Liabilities (2023)

CG Oncology's Preferred Stock Liabilities history spans 1 years, with the latest figure at $22.0 million for Q4 2023.

  • For Q4 2023, Preferred Stock Liabilities changed N/A year-over-year to $22.0 million; the TTM value through Dec 2023 reached $22.0 million, changed N/A, while the annual FY2023 figure was $22.0 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $22.0 million in Q4 2023 per CGON's latest filing, down from $47.3 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $47.3 million in Q1 2023 to a low of $22.0 million in Q2 2023.